Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial
BNN Bloomberg ·
Eli Lilly said on Wednesday its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk’s Ozempic on blood sugar control and delivered more than double the weight loss in a diabetes study.
Publication and source information
- Platform
- NewsTiVi
- Source
- BNN Bloomberg
- Published
- 10/29/2026, 11:32:39 PM
- Country
- Canada
The headline and summary are supplied by the publisher. Read the full report on the source website.
Contact: info@newstivi.com